References 


  1. Mensah GA, Bakris G. The United nations high level meeting addresses noncommunicable diseases, but where is hypertension? J Clin Hypertens (Greenwich) 2011;13:787-790.

  2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-2050.

  3. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. 
Hypertension 2007;49:69-75.

  4. Wolf-Maier K, Cooper RS, Kramer H, et al. 
Hypertension treatment and control in five 
European countries, Canada, and the United 
States. Hypertension 2004;43:10-17.

  5. Dahlöf B, Devereux RB, Kjeldsen SE, et al. 
Cardiovascular morbidity and mortality in the 
Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial 
against atenolol. Lancet 2002;359:995-1003.

  6. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension tr eatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816.

  7. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: 
a scientific statement from the American Heart 
Association Professional Education Committee 
of the Council for High Blood Pressure Research. 
Circulation 2008;117:e510-e526.

  8. Hajjar I, Selim M, Novak P, Novak V. The relationship between nighttime dipping in blood pressure and cerebral hemodynamics in nonstroke patients. J Clin Hypertens (Greenwich ) 2007;9:929-936.

  9. Peralta CA, Hicks LS, Chertow GM, et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005;45:1119-1124.

  10. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-1080.

  11. Lloyd-Jones DM, Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002;40:640-646.

  12. Lewington S, MacMahon S. Blood pressure, cholesterol, and common causes of death: a review. Prospective Studies Collaboration. Am J Hypertens 1999;12:96S-98S.

  13. Freis ED. Veterans Administration Cooperative Study Group on Hypertensive Agents: effects of age on treatment results. Am J Med 1991;90:20S-23S.

  14. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community. Hypertension 2000;36:594-599.

  15. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 1999;34:381-385.

  16. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.

  17. Moser M, Cushman W, Handler J. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich ) 2006;8:434-440.

  18. Kaplan NM. Resistant hypertension. J Hypertens 2005;23:1441-1444.

  19. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol 2007;88:683-692.

  20. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich ) 2008;10:130-139.

  21. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-1757.

  22. Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-37.

  23. Mazzaglia G, Mantovani LG, Sturkenboom MC et al. Patterns of persistence with antihypertensive 
medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005;23:2093-2100.

  24. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-1117.

  25. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-1757.

  26. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002;40:464-469.

  27. Johnson AG. NSAIDs and increased blood 
pressure. What is the clinical significance? 
Drug Saf 1997;17:277-289.

  28. Conlin PR, Moore TJ, Swartz SL. et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000;36:461-465.

  29. Whelton A, White WB, Bello AE, et al. Effects of 
celecoxib and rofecoxib on blood pressure 
and edema in patients > or =65 years of 
age with systemic hypertension and osteoarthritis. 
Am J Cardiol 2002;90:959-963.

  30. He FJ, MacGregor GA. Effect of longer-term 
modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004;(3):CD004937.

  31. Luft FC, Weinberger MH. Review of salt restriction and the response to antihypertensive drugs. Satellite symposium on calcium antagonists. Hypertension 1988;11:I229-I232.

  32. Schafflhuber M, Volpi N, Dahlmann A, et al. Mobilization of osmotically inactive Na+ by growth and by dietary salt restriction in rats. Am J Physiol Renal Physiol 2007;292:F1490-F1500.

  33. Aguilera MT, de la Sierra A, Coca A, et al. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension 1999;33:653-657.

  34. Wildman RP, Gu D, Muntner P, et al. Alcohol 
intake and hypertension subtypes in Chinese men. 
J Hypertens 2005;23:737-743.

  35. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;18:805-812.

  36. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003;41:625-633.

  37. Hall JE, Kuo JJ, da Silva AA, et al. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 2003;12:195-200.

  38. Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep 2009;11:407-413.

  39. Aucott L, Rothnie H, McIntyre L, et al. Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension 2009;54:756-762.

  40. Poobalan AS, Aucott LS, Smith WC, et al. Long-term weight loss effects on all cause mortality in overweight/obese populations. Obes Rev 2007;8:503-513.

  41. He FJ, Marciniak M, Visagie E, et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension 2009;54:482-488.

  42. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;18:805-812.

  43. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.

  44. Appel LJ, Miller ER, III, Jee SH, et al. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation 2000;102:852-857.

  45. Moore TJ, Vollmer WM, Appel LJ, et al. Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Hypertension 1999;34:472-477.

  46. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med 1999;159:285-293.

  47. Czarina Acelajado M, Calhoun DA. Treatment of resistant hypertension. Minerva Cardioangiol 2009;57:787-812.

  48. Graves JW, Bloomfield RL, Buckalew VM, Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 1989;298:361-365.

  49. Taler SJ. Treatment of resistant hypertension. Curr Hypertens Rep 2005;7:323-329.

  50. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich ) 2011;13:146-154.

  51. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.

  52. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.

  53. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-229.

  54. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159-1164.

  55. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358.

  56. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich) 2005;7:354-356.

  57. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930.

  58. Oparil S. The ASCOT blood pressure lowering trial. Curr Hypertens Rep 2006;8:229-231.

  59. Chapman JN, Kirby P, Caulfield MC, Poulter NR. Cardiovascular risk factors in a cohort of 30,000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hum Hypertens 2001;15:S23-S26.

  60. Gheorghiade M, Khan S, Blair JE, et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J 2009;158:437-443.

  61. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-1838.

  62. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.

  63. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217-2226.

  64. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep 2002;4(3):221-228.

  65. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661.

  66. Townsend RR, DiPette DJ, Goodman R, et al. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990;48:665-675.

  67. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-1946.

  68. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-1909.

  69. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.

  70. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;58:765-773.


From the October 01, 2012 Issue of Renal and Urology News

Topics:

Cardiovascular Disease Hypertension